| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a4593098af5062ecc1b104b5bde87ae5 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2072 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2873
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2013
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-145
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2853
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-286
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2886 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-28
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 |
| filingDate |
2016-06-27^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-04-13^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5e352506fbb6ca212ee3dcfd27b2ec99
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ad6a650e9856db48942310e68ab6cf86
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dcae19b298853f3e3754aa76db2b4a50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4b29f98f8b86ee006f52793c68a7a07b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e329be4b3a8482e409bd4e093de9c7a8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50e795e2e060c7b187b1c6a5c9f77002 |
| publicationDate |
2021-04-13^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-10973766-B2 |
| titleOfInvention |
Oral pharmaceutical dosage form for the delivery of a peptide and/or protein |
| abstract |
The invention relates to an oral polymeric pharmaceutical dosage form which comprises a thermoresponsive eutectic composition which is solid at or about room temperature and fluid at or about body temperature, the eutectic composition mixed together with a crosslinking agent and an active pharmaceutical ingredient (API) to form an API loaded region; and a porous polymeric composition at least partially surrounding the API loaded region to protect the API when the dosage form is in a stomach of the human or animal body, the porous polymeric composition allowing the ingress of water to contact the crosslinking agent thereby facilitating the crosslinking agent to cause crosslinking of the porous polymeric composition, which crosslinked porous polymeric composition allows controlled egress of API via egress of fluid thermoresponsive eutectic composition at the intestine. In a preferred embodiment, the dosage form further comprises a coating there around. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11672761-B2 |
| priorityDate |
2015-06-26^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |